Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin

@article{AstonMourney2008TooMO,
  title={Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin},
  author={Kathryn Aston-Mourney and J. Proietto and Grant Morahan and Sofianos Andrikopoulos},
  journal={Diabetologia},
  year={2008},
  volume={51},
  pages={540-545}
}
In many countries, first- or second-line pharmacological treatment of patients with type 2 diabetes consists of sulfonylureas (such as glibenclamide [known as glyburide in the USA and Canada]), which stimulate the beta cell to secrete insulin. However, emerging evidence suggests that forcing the beta cell to secrete insulin at a time when it is struggling to cope with the demands of obesity and insulin resistance may accelerate its demise. Studies on families with persistent hyperinsulinaemic… CONTINUE READING